Table 4:
Quantitative Acceptability Data from Surveys Administered to Adolescents. Quality of Life Questionnaire Summary Scores
| Quality of Life Questionnaire Summary Scores | Cohort 1Ca | Cohort 1Rb | TOTAL | |||
|---|---|---|---|---|---|---|
| Baseline (N=30) Median (IQR) |
Week 16 (N=29) Median (IQR) |
Baseline (N=25) Median (IQR) |
Week 16 (N=23) Median (IQR) |
Baseline (N=55) Median (IQR) |
Week 16 (N=52) Median (IQR) |
|
| Physical functioning dimension | 97 (94, 100) | 97 (91, 100) | 100 (97, 100) | 100 (94, 100) | 100 (94, 100) | 98 (91, 100) |
| Emotional functioning dimension | 90 (80, 100) | 95 (80, 100) | 90 (70, 100) | 95 (90, 100) | 90 (75, 100) | 95 (88, 100) |
| Social functioning dimension | 100 (90, 100) | 100 (95, 100) | 95 (90, 100) | 100 (95, 100) | 100 (90, 100) | 100 (95, 100) |
| School functioning dimension | 80 (70, 90) | 80 (65, 90) | 70 (60, 88) | 85 (80, 95) | 80 (65, 90) | 85 (70, 90) |
| Psychosocial functioning dimension | 90 (82, 97) | 92 (77, 97) | 83 (77, 95) | 92 (87, 97) | 90 (78, 95) | 92 (86, 97) |
| Total functioning dimension | 93 (87, 97) | 94 (83, 97) | 89 (84, 96) | 95 (90, 98) | 91 (84, 96) | 94 (87, 97) |
a
Cohort 1C consisted of participants assigned to receive long-acting cabotegravir injections.
b
Cohort 1R consisted of participants assigned to receive long-acting rilpivirine injections.